Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 9;635(8038):462–471. doi: 10.1038/s41586-024-07943-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Extended Data Fig. 2 — a. PFS (left) and OS (right) with DCT in patient subgroups defined by clinical and molecular characteristics. HRs and 95% CIs were estimated using unstratified Cox proportional hazards models. The analysis of PFS was based on a data cut-off date of July 24, 2019 and the analysis of OS was based on a data cut-off date of March 12, 2021. b. Spider plots, depicting patient-level % change compared to baseline in the size of target lesion(s) (per RECIST v1.1) in patients with STK11 and/or KEAP1-mutated nsNSCLC treated with TDCT (top), DCT (middle) and CT (bottom). Individual trajectories are colour-coded based on best overall response. Only patients with both a baseline and at least one available post-baseline target lesion measurement are included. ORR and mDoR are based on confirmed objective responses by BICR. The analysis was based on a data cut-off date of July 24, 2019. c. OS in molecularly defined subgroups of patients with STK11^MUT and/or KEAP1^MUT metastatic nsNSCLC treated with TDCT vs CT (left) and TDCT vs DCT (right). HRs and 95% CIs were estimated using unstratified Cox proportional hazards models. The analysis was based on a data cut-off date of March 12, 2021.